Sergio Cifuentes Canaval, Medical Oncologist, ASCO International Development and Education Award (IDEA) Recipient – 2025 at Conquer Cancer, the ASCO Foundation, shared a post on X:
“Comparative Table of Pembrolizumab Trials in HCC
Key Takeaways
Only KEYNOTE-224 (Phase II) met its primary endpoint (ORR), but with low clinical impact (ORR 16%).
Both phase III trials (KEYNOTE-240, LEAP-002) failed their primary OS endpoints despite:
- Nominal OS improvements (HR <1)
- Higher ORR in combo arm (LEAP-002)
Context vs. Competitors:
- Atezo+Bev (IMbrave150): Positive OS (HR 0.66, p<0.001)
- Tremeli+Durva (HIMALAYA): Positive OS (HR 0.78, p=0.003)
Conclusion:
Pembro-based regimens consistently underdelivered in HCC pivotal trials, failing to demonstrate statistically significant survival benefits in phase III settings.”
More posts featuring Sergio Cifuentes Canaval.